MORF

Morphic Holding, Inc.

26.33 USD
+0.21 (+0.80%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Morphic Holding, Inc. stock is down -13.42% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 5 June’s closed higher than May.

About Morphic Holding, Inc.

Morphic Holding, Inc. discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the. treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis. and fibrosis diseases. The company is also developing avß6 and avß8 to treat solid tumors.